| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DC20853 | BZ-194 | BZ-194 is a small molecule inhibitor of NAADP action that inhibit NAADP-mediated Ca2+ signaling in T cells, neither interferes with Ca2+ mobilization by IP3 or cyclic ADP-ribose nor with capacitative Ca2+ entry. |
|
| DC20326 | BzDANP | BzDANP is a small molecule modulator of pre-miR-29a maturation by Dicer, effectively stabilizes the C-bulged RNA and suppresses Dicer-mediated processing of pre-miR-29a in a concentration dependent manner.. |
|
| DC26049 | Bz-IEGR-pNA (acetate) Featured | Bz-IEGR-pNA is a colorimetric substrate for Factor Xa. |
|
| DC11453 | Bz-Nle-Lys-Arg-Arg-AMC Featured | Bz-Nle-Lys-Arg-Arg-AMC is a substrate for dengue virus NS2B-NS3 and yellow fever virus NS3 protease. |
|
| DC23462 | C-021 dihydrochloride | C-021 dihydrochloride is a potent and orally bioavailable CCR4 antagonist with IC50 of 0.14 uM and 0.039 uM for inhibition of chemotaxis in human and mouse, respectively.. |
|
| DC23414 | C-021 | C-021 is a potent and orally bioavailable CCR4 antagonist with IC50 of 0.14 uM and 0.039 uM for inhibition of chemotaxis in human and mouse, respectively.. |
|
| DC10864 | C188-9 Featured | C188-9 is a potent inhibitor of STAT3 that binds to STAT3 with high affinity (KD=4.7±0.4 nM). C188-9 is well tolerated in mice, shows good oral bioavailability, and is concentrated in tumors. |
|
| DC20855 | C-215 | C-215 is a novel inhibitor of mycobacterial membrane protein large 3 (MmpL3) with MIC90 of 16 uM against M. tuberculosis.. |
|
| DC10937 | C25-140 Featured | C25-140 is a specific, first-in-class small molecule inhibitor of the TRAF6-Ubc13 interaction, binds TRAF6, inhibits TRAF6-Ubc13 interaction and TRAF6 activity. |
|
| DC10276 | C29 Featured | C29 is a potential TLR2 inhibitor. |
|
| DC11493 | C2BA-4 | C2BA-4(C2BA 4) is a potent, specific human Pregnane X receptor (hPXR) activator with EC50 of 49 nM. |
|
| DC20327 | C450-0730 | C450-0730 is a potent LuxN antagonist that antagonizes LuxN-AI-1 binding with IC50 of 2.7 uM. |
|
| DC20328 | C5-benzyl SAHA | C5-benzyl SAHA is a C5-modified SAHA analog that displays dual selectivity to HDAC6 (IC50=0.27 uM) and HDAC8 (IC50=0.38 uM) over HDAC 1, 2, and 3 (IC50=2.9-5.8 uM). |
|
| DC7658 | C646 Featured | C646 is an inhibitor for histone acetyltransferase, and inhibits p300 with a Ki of 400 nM. Preferentially selective for p300 versus other acetyltransferases. |
|
| DC9528 | C75 (trans) Featured | C75 trans is the trans form of C75; C75 is a potent fatty-acid synthase(FASN) inhibitor with IC50 of 35.4 μM(LNCaP cell Proliferation inhibition). |
|
| DC10419 | C 87 | C87 is a novel small-molecule TNFα inhibitor; potently inhibits TNFα-induced cytotoxicity with an IC50 of 8.73 μM. |
|
| DC7697 | CA-074-Me Featured | CA-074 Me is a selective and cell-permeable inhibitor of cathepsin B. |
|
| DC10330 | PD-1-IN-17 Featured | PD-1-IN-17 has CAS#CAS:1673560-66-1, which is a programmed cell death-1 (PD-1) inhibitor. PD-1-IN-17 was first reported in patent WO2015033301A1, (Compound 4), inhibits 92% splenocyte proliferation at 100 nM. PD-1-IN-17 may be related to CA-170 (AUPM170), which is a potent PD-1 inhibitor and curreently under clinical trials. |
|
| DC8704 | Ca2+ channel agonist 1 | Ca2+ channel agonist 1 is a N-type Ca2+ channel activity agonist, with EC50 of 14.23 uM, also inhibits cdk2 kinase activity with EC50 of 3.34 uM. |
|
| DC10648 | CA4948-Analog Featured | CA4948-Analog is an analog of Emavusertib. It has similar property to CA-4948, which is a potent, and orally active interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor. It was reported in patent WO 2015104688. Emavusertib, also known as CA-4948 i |
|
| DC12044 | CA-5f Featured | CA-5f is a novel late-stage autophagy inhibitor with potent anti-tumor effect against non-small cell lung cancer. |
|
| DC4186 | Cabazitaxel | Cabazitaxel (Jevtana, XRP6258) is a semi-synthetic derivative of a natural taxoid. |
|
| DC9423 | Cabergoline | Cabergoline, an ergot derivative, is a potent dopamine receptor agonist on D2 receptors. |
|
| DC26013 | Cabotegravir Sodium Featured | Cabotegravir is a potent HIV integrase inhibitor as an oral lead-in tablet and long-acting injectable for the treatment and prevention of HIV infection. |
|
| DC8180 | Cabotegravir(GSK744) Featured | Cabotegravir is a potent HIV integrase inhibitor as an oral lead-in tablet and long-acting injectable for the treatment and prevention of HIV infection. |
|
| DC9266 | Cabozantinib S-malate Featured | Cabozantinib S-malate (XL184, BMS-907351) is a potent VEGFR2 inhibitor with IC50 of 0.035 nM and also inhibits c-Met, Ret, Kit, Flt-1/3/4, Tie2, and AXL with IC50 of 1.3 nM, 4 nM, 4.6 nM, 12 nM/11.3 nM/6 nM, 14.3 nM and 7 nM, respectively. |
|
| DC10736 | CaCC(inh)-A01 Featured | CaCC(inh)-A01 is a non-selective inhibitor of calcium-activated chloride channels (CaCCs) that blocks ATP-stimulated chloride conductance in human salivary gland, intestinal, and bronchial epithelium (mean IC50 = 10 µM). |
|
| DC20856 | CAD-031 Featured | CAD-031 (CAD31) is a novel brain penetrant, J147-derivative that has enhanced neurogenic activity over J147 in human neural precursor cells (NPCs). |
|
| DC10457 | Cadazolid (ACT-179811) Featured | Cadazolid (ACT-179811) is a novel fluoroquinolone-oxazolidinone antibiotic and a protein synthesis inhibitor. |
|
| DC5068 | Idelalisib (CAL-101,GS-1101) Featured | CAL-101 is a selective p110δ inhibitor with IC50 of 2.5 nM; shown to have 40- to 300-fold greater selectivity for p110δ thanp110α/β/γ, and 400- to 4000-fold more selectivity to p110δ than C2β, hVPS34, DNA-PK and mTOR. |
|
